PLANIJENS™ LEVO tablets 150mcg+30mcg, 21pcs

PLANIJENS™ LEVO 150mcg+30mcg Tablets Buy Online

Understanding Planigence Levo Tablets

Planigence Levo is a low-dose monophasic combined oral contraceptive containing levonorgestrel and ethinylestradiol. Its primary function is hormonal birth control, offering a reliable method for preventing pregnancy. Understanding its mechanism of action and potential benefits is crucial for informed use.

This medication works by suppressing ovulation, thickening cervical mucus to impede sperm passage, and altering the uterine lining to hinder implantation. The combination of hormones provides a multifaceted approach to contraception. Proper and consistent use is essential for maximum effectiveness.

Planigence Levo tablets are designed for a 21-day cycle followed by a 7-day break. During this break, a withdrawal bleed, similar to a menstrual period, typically occurs. Consistent daily intake at approximately the same time is vital for maintaining contraceptive efficacy.

A Comprehensive Overview

Planigence Levo tablets are a combined oral contraceptive (COC), specifically a low-dose monophasic formulation. This means it delivers a consistent, unchanging dose of two hormones—levonorgestrel, a progestin, and ethinylestradiol, an estrogen—throughout the 21-day cycle. This consistent hormonal delivery contributes to its reliable contraceptive effect. The precise balance of these hormones is key to its efficacy and safety profile.

Each tablet contains 150 mcg of levonorgestrel and 30 mcg of ethinylestradiol. The medication is administered orally, with one tablet taken daily for 21 consecutive days, followed by a seven-day break during which a withdrawal bleed usually occurs. This 21/7 regimen mimics the natural menstrual cycle, providing a predictable pattern for users.

Planigence Levo’s contraceptive mechanism is multifaceted. The primary action involves suppression of ovulation, preventing the release of an egg. Secondly, it thickens cervical mucus, creating a barrier that hinders sperm from reaching the egg. Finally, it alters the uterine lining, making it less receptive to implantation should fertilization occur. These combined actions significantly reduce the likelihood of pregnancy.

The efficacy of Planigence Levo, when used correctly, is high, with a Pearl Index (a measure of contraceptive failure) typically below 1. However, factors such as missed doses or interactions with other medications can influence its effectiveness. It’s crucial to adhere strictly to the prescribed regimen and consult a healthcare professional for any concerns or questions regarding its use.

Mechanism of Action

Planigence Levo’s contraceptive effect stems from a combination of hormonal actions, primarily achieved through the synergistic effects of its two key components: levonorgestrel and ethinylestradiol. These hormones work together to prevent pregnancy via multiple pathways, making it a highly effective method of birth control. The precise interplay of these hormones is crucial for its efficacy.

The primary mechanism is the suppression of ovulation. Ethinylestradiol, the estrogen component, primarily inhibits the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland. This hormonal suppression prevents the maturation and release of an egg from the ovary, thus eliminating a key requirement for fertilization.

Beyond ovulation inhibition, Planigence Levo also alters cervical mucus. The progestin, levonorgestrel, increases the viscosity of cervical mucus, making it significantly thicker and less permeable to sperm. This physical barrier effectively prevents sperm from reaching and fertilizing an egg, even if ovulation were to occur.

Finally, the hormonal combination modifies the uterine lining (endometrium), making it less hospitable for implantation. Even if fertilization does occur, the altered endometrium reduces the chances of a fertilized egg successfully implanting in the uterine wall, further preventing pregnancy. This multifaceted approach ensures a high level of contraceptive effectiveness.

Dosage and Administration

Planigence Levo is administered orally, with one tablet taken daily at approximately the same time each day. Consistency is key to maintaining effective hormone levels and maximizing contraceptive efficacy. Missing doses can significantly reduce the protective effect, increasing the risk of unintended pregnancy.

The 21-day cycle involves taking one tablet daily for three weeks. Following the 21-day period, a seven-day hormone-free interval is observed. During this break, a withdrawal bleed, similar to a menstrual period, typically occurs. This bleed is not a true menstruation, but rather a result of the hormonal fluctuation caused by the cessation of medication.

After the seven-day break, a new pack of Planigence Levo should be started, regardless of whether the bleeding has stopped. It’s crucial to begin the new pack on the same day of the week as the previous pack to maintain a consistent cycle and predictable bleeding pattern. The provided packaging often includes a day-of-the-week tracker to assist with this.

Should a tablet be missed, specific instructions should be followed, typically outlined in the accompanying patient information leaflet. These instructions vary depending on when the missed dose occurs. Consulting a healthcare professional is always recommended if there is uncertainty about how to manage a missed dose or any other concerns related to the medication.

Benefits of Using Planigence Levo

Planigence Levo offers several key advantages beyond its primary function of preventing pregnancy. For many women, the predictable menstrual cycle is a significant benefit. The consistent hormonal levels lead to more regular and lighter periods, often reducing menstrual cramps and associated discomfort. This regularity can improve quality of life for those experiencing irregular or heavy bleeding.

Reduced menstrual flow can also contribute to a decrease in the risk of iron-deficiency anemia. Heavy menstrual bleeding can lead to iron depletion, causing fatigue and other health problems. By lessening blood loss, Planigence Levo helps maintain healthy iron levels. This is especially beneficial for women who already experience anemia or have a predisposition towards it.

Moreover, long-term studies suggest that combined oral contraceptives like Planigence Levo may offer protection against certain gynecological cancers. Evidence indicates a reduced risk of endometrial and ovarian cancers in women who use COCs. This protective effect is thought to be related to the suppression of ovulation and the alteration of hormonal balance within the reproductive system.

Beyond these reproductive health benefits, some women report improvements in acne and other skin conditions associated with hormonal fluctuations. While not a guaranteed outcome, the hormonal balance provided by Planigence Levo can sometimes positively impact skin health. Individual responses to hormonal contraception vary, so it’s essential to consult a healthcare provider to discuss potential benefits and risks.

Pros

• High contraceptive efficacy: When taken correctly, Planigence Levo provides a reliable method of preventing unintended pregnancies, offering peace of mind to users. Its multi-pronged mechanism of action contributes to its effectiveness.
• Regular and lighter periods: Many users experience a reduction in menstrual flow and a more predictable cycle, alleviating discomfort associated with heavy or irregular bleeding. This can significantly improve quality of life.
• Potential reduction in certain cancer risks: Studies have shown a correlation between long-term use of combined oral contraceptives and a decreased risk of endometrial and ovarian cancers, although more research is ongoing.
• Improved acne: Some women report an improvement in acne and other skin conditions related to hormonal fluctuations, although this is not consistently observed across all users.
• Convenience: The daily oral administration is straightforward and easily incorporated into a daily routine. The 21-day cycle with a seven-day break offers predictability and simplicity.
• Non-invasive: Unlike some other contraceptive methods, Planigence Levo doesn’t require surgical procedures or ongoing physical interventions, offering a convenient and discreet option.

Potential Drawbacks

While Planigence Levo offers many benefits, potential drawbacks should be considered. One common side effect is changes in menstrual bleeding patterns, including spotting or breakthrough bleeding, particularly during the initial months of use. These irregularities usually subside as the body adjusts to the hormonal changes. However, persistent or heavy bleeding warrants medical attention.

Mood changes, such as increased irritability, depression, or anxiety, are also possible side effects. The hormonal fluctuations associated with Planigence Levo can affect neurotransmitter levels, influencing mood regulation. If significant mood disturbances occur, consulting a healthcare provider is crucial to explore management options and assess the need for alternative contraception.

Weight changes, both gain and loss, have been reported by some users. Hormonal contraceptives can influence metabolic processes, potentially leading to alterations in appetite and body weight. While these changes are not universally experienced, they should be considered when weighing the benefits and risks of Planigence Levo. Regular monitoring of weight and overall health is advisable.

Other potential side effects include breast tenderness, headaches, nausea, and changes in libido. The severity and frequency of these side effects vary among individuals. It is essential to discuss any concerns or unexpected symptoms with a doctor to determine if adjustments to the medication or alternative treatment strategies are necessary. Open communication with a healthcare professional is key to managing any potential side effects effectively.

Cons

• Risk of side effects: Planigence Levo, like all hormonal contraceptives, carries the potential for side effects, including changes in menstrual bleeding, mood swings, weight fluctuations, breast tenderness, headaches, and nausea. The severity and frequency of these side effects vary significantly between individuals.
• Reduced effectiveness with missed doses: Consistent daily use is crucial for maintaining contraceptive effectiveness. Missing doses, even occasionally, can significantly reduce the protection against pregnancy. Careful adherence to the prescribed regimen is essential.
• Not suitable for everyone: Planigence Levo is contraindicated in individuals with certain medical conditions, such as a history of blood clots, liver disease, or certain types of migraine. A thorough medical evaluation is necessary to determine suitability.
• Does not protect against STIs: Planigence Levo only protects against pregnancy and does not offer protection against sexually transmitted infections (STIs). The use of barrier methods, such as condoms, is recommended for STI prevention.
• Potential for drug interactions: Certain medications can interfere with the effectiveness of Planigence Levo. It’s crucial to inform your doctor about all medications and supplements you are taking to avoid potential interactions.
• Requires consistent daily use: The need for daily pill-taking necessitates consistent effort and responsibility. Forgetting to take a pill can compromise its effectiveness and increase the risk of pregnancy.

Contraindications and Precautions

Planigence Levo is contraindicated in individuals with a history of blood clots (venous thromboembolism or arterial thromboembolism), including deep vein thrombosis, pulmonary embolism, stroke, or heart attack. The hormonal components can increase the risk of blood clot formation, making it unsafe for those with a pre-existing predisposition. Careful evaluation of personal and family history is essential before initiating treatment.

Women with severe liver disease or those with a history of liver tumors should avoid Planigence Levo. The liver plays a crucial role in metabolizing the hormones in this medication, and impaired liver function could lead to adverse effects. Similarly, women with certain types of migraines, especially those with aura, should consult their physician before considering this medication, as the hormones may increase migraine frequency or severity.

Individuals with uncontrolled high blood pressure (hypertension), known diabetes with vascular complications, or a personal or family history of breast cancer should also exercise caution and discuss the risks and benefits with their healthcare provider. Certain other conditions, such as severe kidney disease, or specific genetic conditions that increase the risk of blood clots, require careful consideration before initiating Planigence Levo.

Furthermore, women who are pregnant, breastfeeding, or suspect they may be pregnant should not use Planigence Levo. The hormones in the medication can negatively impact fetal development and may interfere with breastfeeding. It is vital to inform the physician of any pregnancy or breastfeeding status before initiating or continuing use of this medication. Regular checkups and open communication with a healthcare provider are crucial throughout the duration of Planigence Levo use.

Pharmacokinetics

Understanding the pharmacokinetic properties of Planigence Levo’s components, levonorgestrel and ethinylestradiol, is crucial for comprehending its therapeutic effects and potential interactions. Both hormones undergo absorption, distribution, metabolism, and excretion processes that influence their plasma concentrations and duration of action. These processes are complex and involve multiple organs and enzymatic pathways.

Following oral administration, levonorgestrel is rapidly and almost completely absorbed. It achieves peak plasma concentrations within approximately one hour. A significant portion binds to plasma proteins, primarily sex hormone-binding globulin (SHBG), which influences its distribution and metabolic clearance. The unbound fraction is responsible for the pharmacological effects. Levonorgestrel undergoes extensive hepatic metabolism, primarily via CYP3A4, and is eliminated via both renal and fecal pathways. Its elimination half-life is relatively long, influencing its sustained contraceptive effect.

Ethinylestradiol, the estrogenic component, also exhibits rapid and complete absorption after oral administration, although peak plasma levels are reached slightly later, around 12 hours. Similar to levonorgestrel, ethinylestradiol is extensively bound to plasma proteins. It undergoes extensive first-pass metabolism in the liver, influencing its bioavailability. The primary metabolic pathways involve aromatic hydroxylation. The metabolites are subsequently eliminated mainly through the kidneys and intestines. The relatively short elimination half-life of ethinylestradiol contributes to the cyclical nature of the hormonal effects.

The pharmacokinetic interactions between levonorgestrel and ethinylestradiol are noteworthy. Ethinylestradiol induces SHBG synthesis, which in turn affects the binding and metabolism of levonorgestrel. This interaction contributes to the overall hormonal balance and contraceptive efficacy. Individual variations in metabolism can influence the plasma concentrations and the duration of action of both hormones. This highlights the importance of individual patient considerations when prescribing and monitoring Planigence Levo.

Important Considerations

Absorption and Metabolism

Following oral ingestion, both levonorgestrel and ethinylestradiol, the active components of Planigence Levo, are absorbed rapidly and extensively from the gastrointestinal tract. The absorption process is influenced by various factors, including gastric emptying time and the presence of food. Once absorbed, these hormones are distributed throughout the body, binding to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG).

The metabolism of levonorgestrel primarily occurs in the liver, involving the cytochrome P450 enzyme system, specifically CYP3A4. This enzymatic pathway leads to the formation of various metabolites, which are subsequently excreted via both renal (urine) and biliary (feces) routes. The elimination half-life of levonorgestrel is relatively long, contributing to its sustained effects.

Similarly, ethinylestradiol undergoes extensive first-pass metabolism in the liver, primarily through aromatic hydroxylation and subsequent conjugation reactions. The resulting metabolites are then eliminated primarily through the kidneys and intestines. Ethinylestradiol’s metabolism is also influenced by the activity of various enzymes, and individual variations in enzyme activity can lead to differences in the rate of metabolism and plasma concentration.

The interplay between the absorption, distribution, metabolism, and excretion of these two hormones is complex and dynamic. Factors such as individual variations in enzyme activity, genetic polymorphisms, and concomitant medications can influence these processes, potentially affecting the overall efficacy and safety profile of Planigence Levo. This underscores the importance of individualized patient assessment and careful consideration of potential drug interactions.